OR WAIT null SECS
© 2022 MJH Life Sciences and Practical Cardiology. All rights reserved.
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
November 06, 2022
The late-breaking findings suggest the potential prognostic benefit of highly purified EPA in patients with chronic CAD with a low EPA/AA ratio.
Over a six-month period, SGLT2 inhibition with empagliflozin did not change left ventricular structure or function compared with placebo in people without diabetes or significant heart failure.
November 05, 2022
Risk stratification in the emergency department led to a 12% lower risk of death from any cause or hospitalization for cardiovascular causes compared with usual care.